Criteria-Based Consultation Prescribing Program CRITERIA FOR DRUG COVERAGE

Vonoprazan 10 mg (Voquezna 10 mg)

Notes:

- Quantity Limits: Yes
- ^ Adequate trial is defined as 14-day treatment duration
- * Intolerance excludes adverse drug reactions that are expected, mild in nature, resolve with continued treatment, and do not require medication discontinuation
- **Treatment duration = 4 weeks for non-erosive gastroesophageal reflux disease and 6 months for erosive gastroesophageal reflux disease

Initiation (new start) criteria and criteria for new members entering Kaiser Permanente already taking the medication who have not been reviewed previously: Non-formulary vonoprazan 10 mg tablet (Voquezna 10 mg) will be covered for on the prescription drug benefit for the appropriate treatment duration** when the following criteria are met:

- 1. Prescriber is a gastroenterologist and patient has a diagnosis of erosive or nonerosive gastroesophageal reflux disease
 - Patient has failed an adequate trial[^], or has an allergy or intolerance^{*} to all of the following medications:
 - Omeprazole (at least 40 mg per day)
 - Pantoprazole (at least 40 mg per day)
 - Lansoprazole (at least 30 mg per day)
 - Rabeprazole (at least 20 mg per day)
 - Esomeprazole (at least 40 mg per day)
 - Dexlansoprazole (criteria based) (at least 60 mg per day)

kp.org

Revised: 04/10/25 Effective: 06/19/25 All plans offered and underwritten by Kaiser Foundation Health Plan of the Northwest

